MX2016012124A - Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos. - Google Patents

Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.

Info

Publication number
MX2016012124A
MX2016012124A MX2016012124A MX2016012124A MX2016012124A MX 2016012124 A MX2016012124 A MX 2016012124A MX 2016012124 A MX2016012124 A MX 2016012124A MX 2016012124 A MX2016012124 A MX 2016012124A MX 2016012124 A MX2016012124 A MX 2016012124A
Authority
MX
Mexico
Prior art keywords
composition
same
antibodies against
against immunogenic
immunogenic glycopeptides
Prior art date
Application number
MX2016012124A
Other languages
English (en)
Inventor
Chang Chih-Long
Wu Chao-Chih
Original Assignee
Mackay Medical Found The Presbyterian Church In Taiwan Mackay Memorial Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mackay Medical Found The Presbyterian Church In Taiwan Mackay Memorial Hospital filed Critical Mackay Medical Found The Presbyterian Church In Taiwan Mackay Memorial Hospital
Publication of MX2016012124A publication Critical patent/MX2016012124A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001173—Globo-H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen en la presente anticuerpos que se unen específicamente a al menos un epítopo definido por el glicopéptido inmunogénico. Otros aspectos de la presente descripción son una composición farmacéutica que comprende el anticuerpo; y un método para prevenir y/o tratar cáncer Globo H positivo.
MX2016012124A 2014-03-19 2015-03-19 Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos. MX2016012124A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461955216P 2014-03-19 2014-03-19
PCT/US2015/021413 WO2015143123A2 (en) 2014-03-19 2015-03-19 Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof

Publications (1)

Publication Number Publication Date
MX2016012124A true MX2016012124A (es) 2017-04-06

Family

ID=54145306

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012124A MX2016012124A (es) 2014-03-19 2015-03-19 Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.

Country Status (11)

Country Link
US (4) US20170143810A1 (es)
EP (2) EP3119432B1 (es)
JP (1) JP2017518958A (es)
KR (1) KR20170003912A (es)
CN (2) CN107073088A (es)
AU (1) AU2015231256A1 (es)
CA (2) CA2943333A1 (es)
IL (1) IL247659A0 (es)
MX (1) MX2016012124A (es)
TW (2) TW201622743A (es)
WO (2) WO2015143123A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014296038B2 (en) 2013-07-31 2020-09-10 Bioventures, Llc. Compositions for and methods of treating and preventing cancer targeting tumor associated carbohydrate antigens
AU2014391422A1 (en) 2013-09-17 2015-12-17 Obi Pharma, Inc. Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
WO2015143123A2 (en) 2014-03-19 2015-09-24 Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
BR112016020009A2 (pt) 2014-04-10 2017-10-17 Obi Pharma Inc anticorpo, composição farmacêutica, método para inibir a proliferação de células cancerígenas, hibridoma
AR105910A1 (es) 2015-09-04 2017-11-22 Obi Pharma Inc Matrices de glicano y método de uso
US20180264093A1 (en) * 2015-09-18 2018-09-20 Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation Immunogenic glycopeptide compounds, pharmaceutical compositions and uses thereof
CA3000531A1 (en) 2015-10-07 2017-04-13 Obi Pharma, Inc. Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
KR20180121786A (ko) 2016-03-29 2018-11-08 오비아이 파머 인코퍼레이티드 항체, 제약 조성물 및 방법
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
TWI697333B (zh) 2016-04-22 2020-07-01 台灣浩鼎生技股份有限公司 經由Globo系列抗原之免疫活化或免疫調節之癌症免疫療法
KR20190067765A (ko) 2016-07-27 2019-06-17 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
KR102528998B1 (ko) * 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
WO2018054353A1 (en) * 2016-09-23 2018-03-29 Chang, Chih-Long Anti-globo h antibodies
WO2018094414A1 (en) 2016-11-21 2018-05-24 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
CN111032083B (zh) * 2017-05-24 2024-01-12 财团法人生物技术开发中心 抗globo h的人源化抗体及其在癌症治疗中的用途
JP7264831B2 (ja) * 2017-06-15 2023-04-25 ディベロップメント センター フォー バイオテクノロジー 抗ｇｌｏｂｏ ｈ抗体を含有する抗体－薬物コンジュゲートおよびその使用
TWI789399B (zh) * 2017-06-22 2023-01-11 財團法人生物技術開發中心 不對稱異二聚fc-scfv融合抗globo h及抗cd3雙特異性抗體及其於癌症治療上之用途
WO2019217450A1 (en) * 2018-05-08 2019-11-14 Rhode Island Hospital Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
KR20210031651A (ko) * 2018-06-01 2021-03-22 오비아이 파머 인코퍼레이티드 항-음성 면역 관문 항체와 항-globo h 또는 항-ssea-4 항체를 사용한 병용 요법
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
BR112021004553A2 (pt) * 2018-09-17 2021-06-08 Abcuro, Inc. anticorpos anti-klrg1
EP3799881A1 (en) * 2019-10-04 2021-04-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Single domain antibodies specifically binding globo - series glycans
CN110665001A (zh) * 2019-11-14 2020-01-10 上海农林职业技术学院 一种水性复合佐剂、其应用及猫用疫苗
CN112675298B (zh) * 2020-12-28 2024-05-03 中国医学科学院医学生物学研究所 一种免疫佐剂、含有所述免疫佐剂的疫苗及制备方法和应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050049197A1 (en) 1993-09-14 2005-03-03 Epimmune Inc. Induction of immune response against desired determinants
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
WO1995007707A1 (en) 1993-09-14 1995-03-23 Cytel Corporation Alteration of immune response using pan dr-binding peptides
US6544952B1 (en) 1994-03-15 2003-04-08 Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the globo-H epitope and uses thereof
PT876398E (pt) * 1996-01-24 2002-12-31 Epimmune Inc Inducao de respostas imunitarias contra determinantes desejados
US6676946B2 (en) 1997-03-27 2004-01-13 Institut Pasteur Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
AU2005227896B2 (en) * 2004-03-23 2008-11-13 Eli Lilly And Company Anti-myostatin antibodies
JP4702950B2 (ja) * 2005-03-28 2011-06-15 キヤノン株式会社 電子写真感光体、プロセスカートリッジおよび電子写真装置、ならびに、電子写真感光体の製造方法
US20070202578A1 (en) 2005-08-26 2007-08-30 Centre National De La Recherche Scientifique (Cnrs) Production of globosides oligosaccharides using metabolically engineered microorganisms
ES2533464T3 (es) * 2005-10-06 2015-04-10 Eli Lilly And Company Anticuerpos anti-miostatina
US8128926B2 (en) * 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
JP2011512332A (ja) 2008-02-11 2011-04-21 キュアー テック リミテッド 腫瘍治療のためのモノクローナル抗体
EP2285831A4 (en) 2008-05-07 2011-05-04 Innovative Biosensors Inc REAGENTS, METHODS, AND SYSTEMS FOR DETECTION OF METHICILLIN-RESISTANT STAPHYLOCOCCUS (MRSA)
US20090317411A1 (en) 2008-06-16 2009-12-24 Academia Sinica Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment
US8158367B2 (en) 2008-06-16 2012-04-17 Academia Sinica Cancer diagnosis based on levels of antibodies against Globo H and its fragments
EP2315771A4 (en) 2008-07-11 2012-02-01 Sloan Kettering Inst Cancer GLYCOPEPTIDE CONSTRUCTS AND ITS USE
US7928077B2 (en) 2008-07-11 2011-04-19 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies
WO2010127180A2 (en) * 2009-04-30 2010-11-04 University Of Rochester Dc-stamp antibodies
KR101677279B1 (ko) * 2009-06-16 2016-11-29 아카데미아 시니카 신규한 당지질 애주번트를 갖는 ｇｌｏｂｏ ｈ 및 관련 항암 백신
EP2481752B1 (en) 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
TW201118166A (en) * 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
RS55670B1 (sr) * 2010-03-15 2017-06-30 Academisch Ziekenhuis Leiden Peptidi, konjugati i metod za povećanje imunogenosti vakcine
AU2011235833A1 (en) * 2010-04-02 2012-10-25 Kalobios Pharmaceuticals, Inc. Generation of antibodies to an epitope of interest
ES2566602T3 (es) 2010-04-09 2016-04-14 Aveo Pharmaceuticals, Inc. Anticuerpos anti-ErbB3
NZ604089A (en) 2010-06-11 2015-03-27 Sloan Kettering Inst Cancer Multivalent glycopeptide constructs and uses thereof
CN103209701B (zh) * 2010-06-11 2016-08-03 乔治亚大学研究基金公司 免疫原性疫苗
TWI609882B (zh) * 2012-05-22 2018-01-01 必治妥美雅史谷比公司 雙特異性抗體及其使用方法
EP3689370A1 (en) 2012-12-21 2020-08-05 Aveo Pharmaceuticals Inc. Anti-gdf15 antibodies
JP6359561B2 (ja) 2013-01-04 2018-07-18 オービーアイ ファーマ インコーポレイテッド 高い炭水化物抗原密度を有するワクチン及び新規サポニンアジュバント
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
AU2014391422A1 (en) 2013-09-17 2015-12-17 Obi Pharma, Inc. Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
EP3054974A4 (en) 2013-10-10 2017-06-14 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2015143123A2 (en) 2014-03-19 2015-09-24 Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
BR112016020009A2 (pt) 2014-04-10 2017-10-17 Obi Pharma Inc anticorpo, composição farmacêutica, método para inibir a proliferação de células cancerígenas, hibridoma

Also Published As

Publication number Publication date
KR20170003912A (ko) 2017-01-10
EP3119432B1 (en) 2020-01-08
US20170143810A1 (en) 2017-05-25
JP2017518958A (ja) 2017-07-13
US20180371103A1 (en) 2018-12-27
WO2015143126A1 (en) 2015-09-24
AU2015231256A1 (en) 2016-09-22
CN106456766B (zh) 2020-03-10
TW201622743A (zh) 2016-07-01
WO2015143123A3 (en) 2015-11-26
CA2943333A1 (en) 2015-09-24
US9828436B2 (en) 2017-11-28
IL247659A0 (en) 2016-11-30
US9951143B2 (en) 2018-04-24
EP3119432A4 (en) 2017-09-13
CA2943334A1 (en) 2015-09-24
US20170107297A1 (en) 2017-04-20
EP3119432A2 (en) 2017-01-25
US20170362337A1 (en) 2017-12-21
CN106456766A (zh) 2017-02-22
TWI681972B (zh) 2020-01-11
TW201623336A (zh) 2016-07-01
CN107073088A (zh) 2017-08-18
EP3119424A4 (en) 2017-09-13
WO2015143123A2 (en) 2015-09-24
EP3119424A1 (en) 2017-01-25

Similar Documents

Publication Publication Date Title
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
NZ738008A (en) Tigit-binding agents and uses thereof
MX2022003891A (es) Anticuerpos anti-muc16 y sus usos.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
EA201892294A1 (ru) Антитела и композиции против tim-3
AU2018253589A1 (en) Antibodies, pharmaceutical compositions and uses thereof
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
JO3772B1 (ar) صيغة جسم مضاد لـ cgrp
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
PH12018501043A1 (en) Site specific her2 antibody drug conjugates
EA201790173A1 (ru) Антитела, связывающие axl
PH12016501366A1 (en) Novel anti-baff antibodies
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
MX2023006415A (es) Anticuerpos, usos y metodos.
MY186711A (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
WO2018089807A3 (en) Anti-cd46 antibodies and methods of use
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
EP4218817A3 (en) Methods for treating metabolic diseases by inhibiting myostatin activation